Segments - Clinical Laboratory Tests Market by Types (Complete Blood Count, HGB/HCT tests, Basic Metabolic Panel , BUN Creatinine tests, Electrolyte Testing, HbA1c tests, Comprehensive Metabolic Panel, Liver Panel [Hepatitis, Bile Duct Obstruction, Liver Cirrhosis, Liver Cancer, Bone disease, Autoimmune Disorders, and Others], Renal Panel, and Lipid Panel), End-users (Central Laboratories [Complete Blood Count, HGB/HCT, Basic Metabolic Panel, BUN Creatinine Tests, Electrolytes Testing, HbA1c Tests, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, and Lipid Panel], and Primary Clinics[Complete Blood Count, HGB/HCT, Basic Metabolic Panel, BUN Creatinine Tests, Electrolytes Testing, HbA1c Tests, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, and Lipid Panel]), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031
The global clinical laboratory tests market size was valued at USD 103.67 Billion in 2022 and is projected to reach USD 232.71 Billion by 2031, expanding at a CAGR of 9.4% during the forecast period 2023 - 2031. The growth of the market is attributed to the growing awareness in health-conscious population and rising presence of chronic diseases.
Clinical laboratory tests refer to a range of medical tests implemented in a laboratory equipped with all aspects of laboratory instruments and medicine. These tests are done for gathering information about the health of patients, diagnosis of disease, and treating their respective condition. In 2019, International Diabetes Federation published an article and stated that approximately 464 million people were suffering from diabetes and was projected to reach 705 million worldwide by 2045.
Moreover, rising geriatric population and their higher risks of exposing to diseases is a major aspect for the expansion of the clinical laboratory tests. As per the data published by the World Population Prospects in 2019, one in 11 people globally were aged over 65 years and, by 2050, it was projected to become one in six people for people having the aged of 65 years and above.
To diagnose age-related diseases, the use for clinical laboratory tests are rising. Other factors such as rising cases of obesity due to lack of proper exercise and consumption of unhealthy food are anticipated to lead the occurrence of several chronic diseases. The demand for clinical laboratory tests is projected to propel significantly due to increasing awareness of regular body profiling between healthcare professionals and patients internationally.
The report on the global clinical laboratory tests market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Clinical Laboratory Tests Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016 – 2021 |
Forecast Period |
2023 – 2031 |
Segmentation |
Types (Complete Blood Count, HGB/HCT tests, Basic Metabolic Panel , BUN Creatinine tests, Electrolyte Testing, HbA1c tests, Comprehensive Metabolic Panel, Liver Panel [Hepatitis, Bile Duct Obstruction, Liver Cirrhosis, Liver Cancer, Bone disease, Autoimmune Disorders, and Others], Renal Panel, and Lipid Panel), End-users (Central Laboratories [Complete Blood Count, HGB/HCT, Basic Metabolic Panel, BUN Creatinine Tests, Electrolytes Testing, HbA1c Tests, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, and Lipid Panel], and Primary Clinics [Complete Blood Count, HGB/HCT, Basic Metabolic Panel, BUN Creatinine Tests, Electrolytes Testing, HbA1c Tests, Comprehensive Metabolic Panel, Liver Panel, Renal Panel, and Lipid Panel]), |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Abbott, ARUP Laboratories, OPKO Health, Inc., Bioscientia Institut für Medizinische Diagnostik GmbH, Charles River, NeoGenomics Laboratories, Inc., Genoptix, Inc., Healthscope Ltd., Labco, Laboratory Corporation of America Holdings (LabCorp), Fresenius Medical Care; QIAGEN, Quest Diagnostics, Siemens Healthcare Private Limited, Tulip Diagnostics (P) Ltd., Sonic Healthcare, Merck KgaA, and Biosino Bio-technology and Science Inc. |
Based on end-users, the global clinical laboratory tests market is bifurcated into central laboratories and primary clinics. The central laboratories segment is further divided into complete blood count, HGB/HCT, basic metabolic panel, BUN creatinine tests, electrolytes testing, HbA1c tests, comprehensive metabolic panel, liver panel, renal panel, and lipid panel.
The central laboratories segment is projected to hold a substantial share of the market in the coming years owing to wide conduction of laboratory tests for various applications such as diseases treatment research and drug discovery. Covance Inc., Eurofins Scientific, Pharmaceutical Product Development and LLC, CIRION BioPharma Research Inc., Phoenix Lab, and Q2 Solutions are some central laboratories present in the market, which fuel the segment growth.
On the other hand, the primary clinics segment is anticipated to register a rapid growth rate during the forecast period as the demand for rapid test results at primary clinical centers are rising significantly due to easy accessibility. Increasing awareness related to laboratory tests in clinics is further expected to drive the market growth during the forecast period. Additionally, introducing advanced technology such as rapid and portable analyzers in the clinics are also estimated to drive the segment growth.
On the basis of types, the clinical laboratory tests market share is divided into complete blood count (CBC), HGB/HCT, basic metabolic panel (BMP), BUN creatinine tests, electrolyte testing, HbA1c tests, comprehensive metabolic panel (CMP), liver panel, renal panel, and lipid panel tests. The liver panel segment is further categorized as hepatitis, bone disease, autoimmune disorders, liver cancer, liver cirrhosis, and bile duct obstruction.
The BMP segment held a major market share in 2019 and is projected to account for a key share of the global clinical laboratory tests market in the coming years. Growing occurrence of lifestyle-induced diseases such as obesity and metabolic abnormalities are key drivers for wide adoption of the testing type. However, the lipid panel tests segment is projected to grow at a faster rate during the forecast period owing to rising awareness about the prevalence of cardiovascular disorders and diabetes.
Meanwhile, the liver panel segment is projected to constitute a large market share during the forecast period because of rising prevalence of liver-related disorders such as hepatitis and other diseases. Increasing number of lifestyle disorders as well as increasing consumption of tobacco and alcohol are key drivers for the wide adoption of the testing, thereby, boosting the segment growth.
In terms of regions, the global clinical laboratory tests market is classified as North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America dominated the market by representing a key share in 2020 and is anticipated to continue its domination in the market during the forecast period.
Rising test volumes and growing penetration of advanced diagnostic techniques are key factors pushing the regional market growth. Moreover, growing incidences of cancer and rising generic population are anticipated to rise the demand for clinical laboratory tests in the region.
On the other hand, the market in Asia Pacific is projected to register a substantial CAGR during the forecast period. Wide implementation of advanced diagnostic technologies and massive supported from governments for the improvement in the healthcare infrastructure by emerging economies such as China and India. Furthermore, positive economic growth, growing scientific research, and unmet medical needs are some untapped opportunities which are primary drivers the regional market growth.
Some of the key players competing in the market are Abbott, ARUP Laboratories, OPKO Health, Inc., Bioscientia Institut für Medizinische Diagnostik GmbH, Charles River, NeoGenomics Laboratories, Inc., Genoptix, Inc., Healthscope Ltd., Labco, Laboratory Corporation of America Holdings (LabCorp), Fresenius Medical Care; QIAGEN, Quest Diagnostics, Siemens Healthcare Private Limited, Tulip Diagnostics (P) Ltd., Sonic Healthcare, Merck KgaA, and Biosino Bio-technology and Science Inc.
Major players are mostly focusing on mergers, acquisitions, and strategic partnerships for growing their presence in clinical laboratory tests market. For instance, in 2018, Charles River acquired MPI research which was leading non-clinical contract research organization. The deal was primarily aimed to deliver comprehensive testing services to many medical device and biopharmaceutical companies.